Voyager Therapeutics, Inc. - VYGR STOCK NEWS

Voyager Therapeutics (VYGR) announced significant updates in its pipeline, focusing on second-generation programs for Huntington’s disease, ALS, spinal muscular atrophy, and GBA1 mutation-related diseases, utilizing proprietary AAV capsids. The TRACER platform aims to discover targeted AAV capsids for various tissues. Financially, collaboration revenue dropped to $1.4 million in Q2 2021 from $28.7 million in Q2 2020, while net loss increased to $30.1 million. The company maintains a cash position of $143 million, sufficient for operations into early 2023.

Voyager Therapeutics (NASDAQ: VYGR) announces a strategic shift towards enhancing its gene therapy pipeline, particularly focusing on VY-HTT01 for Huntington's disease. Michael Higgins steps in as interim CEO following Andre Turenne's resignation, while Glenn Pierce assumes the role of interim CSO. The company aims to maximize its TRACER gene therapy platform, which has shown promising transgene expression in non-human primates. Upcoming milestones include the initiation of a Phase 1/2 clinical trial for VY-HTT01 in Q4 2021, emphasizing the potential of its next-generation AAV capsids.

Voyager Therapeutics (NASDAQ: VYGR) presented new preclinical data on a vectorized anti-tau antibody at the 24th Annual Meeting of the American Society of Gene and Cell Therapy. The data indicates durable expression within the central nervous system, which may provide a novel single-dose strategy for treating tauopathies like Alzheimer's. Key findings include a 59% reduction in tau pathology after intravenous administration in rodent models and lasting expression for at least 28 days. A virtual investor event is planned for July 2021 to discuss further developments.

Voyager Therapeutics (NASDAQ: VYGR) presented preclinical data at the 24th Annual Meeting of the American Society of Gene and Cell Therapy, showing significant advancements in gene therapy for neurological diseases. Their novel AAV capsids demonstrated up to 1000-fold higher transgene expression in the brain compared to traditional AAV therapy after intravenous administration. The lead candidate, TRACER 9P801, exhibited a favorable tolerability profile with no observed toxicity. This breakthrough underscores the potential for treating CNS disorders with lower doses than current AAV serotypes.

Voyager Therapeutics (VYGR) reported Q1 2021 financial results, highlighting progress in its Huntington's disease program, VY-HTT01. The FDA cleared its IND application, with plans to initiate a Phase 1/2 trial by Q4 2021. The company also developed novel AAV capsids that improve gene delivery. However, collaboration revenues dropped to $6.5 million from $18.1 million a year prior, with a net loss of $21.6 million. The company has $153.1 million in cash as of March 31, 2021, positioning itself for upcoming trials and innovations.

Voyager Therapeutics (Nasdaq: VYGR) announced significant data presentations at the ASGCT 24th Annual Meeting, scheduled for May 11-14, 2021. Key highlights include:

• First reporting on novel capsid technology.
• Oral presentations on RNA-driven AAV capsid evolution, anti-Tau antibody efficacy in mouse models, and capsid separation techniques.
• Poster presentations on AAV gene therapy for chronic pain and AAV vector ultrafiltration.
• Industry symposium on advancing AAV gene therapy for CNS diseases.

For more information, visit Voyager's website.

Voyager Therapeutics (Nasdaq: VYGR) announced the FDA has lifted the clinical hold on its IND application for VY-HTT01, a gene therapy for Huntington’s disease. The therapy aims to reduce the expression of the huntingtin gene to alter disease progression. The Phase 1/2 clinical trial, named VYTAL, will evaluate the safety and tolerability of VY-HTT01 in early-stage HD patients. This trial is a crucial step as there are currently no approved disease-modifying therapies for HD, which affects over 30,000 individuals in the U.S. with debilitating symptoms.

Voyager Therapeutics (NASDAQ: VYGR) has made significant progress in its lead program, VY-HTT01, for Huntington's disease, aiming to respond to FDA requests regarding its Investigational New Drug (IND) application by mid-2021. The company reported a fourth quarter 2020 net loss of $15.9 million, with total collaboration revenues of $6.5 million for the quarter, down from $32.7 million in Q4 2019. R&D expenses decreased to $22.0 million in Q4 2020, while cash and equivalents were $174.8 million as of December 31, 2020, expected to fund operations into mid-2022.

Voyager Therapeutics (NASDAQ: VYGR) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. A conference call is scheduled for 4:30 p.m. EST to discuss the results and provide a corporate update. Participants can access the call via a designated phone number or through a live webcast on the company's website. Additionally, Voyager will take part in the Cowen 41st Annual Health Care Conference on March 1, 2021 at 11:40 a.m. EST.